Loading clinical trials...
Loading clinical trials...
Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene
Conditions
Interventions
Sulfonylurea
Locations
4
United States
University of Chicago
Chicago, Illinois, United States
University of Rome
Rome, Italy
University of Bergen
Bergen, Norway
University of Exeter
Exeter, United Kingdom
Start Date
July 1, 2016
Primary Completion Date
August 1, 2025
Completion Date
December 31, 2025
Last Updated
June 13, 2024
NCT07439276
NCT06019182
NCT07420829
NCT04096430
NCT04395495
NCT07059858
Lead Sponsor
Royal Devon and Exeter NHS Foundation Trust
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions